Who / What
Pembrolizumab is a pharmaceutical drug, specifically a humanized monoclonal antibody, used in cancer immunotherapy. It functions as a PD-1 inhibitor and is administered by slow intravenous injection to treat various types of cancer.
Background & History
Pembrolizumab was developed as part of cancer immunotherapy research focusing on immune checkpoint inhibitors. It received its initial FDA approval in 2014 for advanced melanoma, marking a significant milestone in oncology. The drug's development built upon scientific discoveries about the PD-1 pathway's role in cancer immune evasion.
Why Notable
Pembrolizumab represents a breakthrough in cancer treatment by harnessing the body's immune system to fight cancer cells rather than directly targeting tumors. It has demonstrated effectiveness across multiple cancer types, including melanoma, lung cancer, and Hodgkin lymphoma. The drug has significantly improved survival rates for patients with certain advanced cancers where treatment options were previously limited.
In the News
Pembrolizumab continues to be relevant due to ongoing research expanding its applications to additional cancer types. Recent clinical trials continue to evaluate its efficacy in combination with other therapies, maintaining its position at the forefront of cancer immunotherapy developments.